Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Inclusion criteria: * Male or female patients ≥ 18 years of age without prior history of deferasirox treatment * β-thalassemia patients receiving regular transfusions every 2-5 weeks * Transfusion history of ≥ 20 units of packed red blood cells Exclusion criteria: * Abnormal renal function at baseline * ALT greater than 5 x ULN at screening * Patients with underlying cardiac disease requiring continuous iron chelation therapy Other protocol-defined inclusion/exclusion criteria may apply.